TECHWIRE 30
(CIX: WRAL30)  910.15  down arrow-11.76  (-1.28 %)  Updated: 06:40 PM EDT, Jun 19 2013
(NQ: Apple)  423.00  down arrow-8.77  (-2.03 %)  Updated: 04:00 PM EDT, Jun 19 2013
(NY: Quintiles)  43.79  down arrow-0.1  (-0.23 %)  Updated: 06:40 PM EDT, Jun 19 2013
(OP: BASF SE)  97.15  down arrow-2.71  (-2.71 %)  Updated: 05:20 PM EDT, Jun 19 2013
(NQ: BioCryst)  1.71  down arrow-0.08  (-4.47 %)  Updated: 04:00 PM EDT, Jun 19 2013
(NQ: BioDelivery)  4.53  down arrow-0.13  (-2.79 %)  Updated: 04:00 PM EDT, Jun 19 2013
(NQ: CEMP)  7.32  up arrow+0.19  (2.66 %)  Updated: 04:00 PM EDT, Jun 19 2013
(NQ: Cisco Systems)  24.68  down arrow-0.14  (-0.56 %)  Updated: 04:00 PM EDT, Jun 19 2013
(NQ: Cornerstone)  8.35  down arrow-0.1  (-1.18 %)  Updated: 04:00 PM EDT, Jun 19 2013
(NQ: Cree)  65.05  down arrow-0.65  (-0.99 %)  Updated: 04:00 PM EDT, Jun 19 2013
(NQ: DARA)  0.67  down arrow-0.02  (-2.88 %)  Updated: 03:59 PM EDT, Jun 19 2013
(NY: EMC Corp.)  24.86  down arrow-0.13  (-0.52 %)  Updated: 06:40 PM EDT, Jun 19 2013
(NQ: Extreme Networks)  3.53  down arrow-0.02  (-0.56 %)  Updated: 04:00 PM EDT, Jun 19 2013
(NQ: Facebook)  24.31  up arrow+0.1  (0.41 %)  Updated: 04:00 PM EDT, Jun 19 2013
(NY: GlaxoSmithKline)  51.48  down arrow-0.99  (-1.89 %)  Updated: 06:40 PM EDT, Jun 19 2013
(NQ: Google)  900.68  up arrow+0.06  (0.01 %)  Updated: 04:00 PM EDT, Jun 19 2013
(NY: IBM)  201.94  down arrow-2.93  (-1.43 %)  Updated: 06:40 PM EDT, Jun 19 2013
(NY: LH)  100.01  down arrow-0.77  (-0.76 %)  Updated: 06:40 PM EDT, Jun 19 2013
(OP: Lenovo Group)  18.70  down arrow-0.44  (-2.3 %)  Updated: 05:20 PM EDT, Jun 19 2013
(NY: MRK)  47.58  down arrow-0.17  (-0.36 %)  Updated: 06:40 PM EDT, Jun 19 2013
(NQ: Microsoft Corp)  34.59  down arrow-0.39  (-1.11 %)  Updated: 04:00 PM EDT, Jun 19 2013
(NQ: NetApp)  38.98  down arrow-0.41  (-1.04 %)  Updated: 04:00 PM EDT, Jun 19 2013
(NY: Novartis AG ADS)  71.90  down arrow-1.22  (-1.67 %)  Updated: 06:40 PM EDT, Jun 19 2013
(OP: Novozymes A/S)  34.00  down arrow-0.71  (-2.05 %)  Updated: 05:20 PM EDT, Jun 19 2013
(NY: Pfizer)  29.10  down arrow-0.3  (-1.02 %)  Updated: 06:40 PM EDT, Jun 19 2013
(NQ: Pozen)  4.96  down arrow-0.16  (-3.13 %)  Updated: 04:00 PM EDT, Jun 19 2013
(NY: Red Hat)  46.22  down arrow-0.41  (-0.88 %)  Updated: 06:40 PM EDT, Jun 19 2013
(NQ: BBRY)  14.18  down arrow-0.66  (-4.44 %)  Updated: 04:00 PM EDT, Jun 19 2013
(NQ: Salix)  66.42  down arrow-0.41  (-0.61 %)  Updated: 04:00 PM EDT, Jun 19 2013
(NQ: SQI)  23.48  down arrow-0.1  (-0.42 %)  Updated: 04:00 PM EDT, Jun 19 2013

Posts tagged “BDSI”

Updated November 11, 2011

Premium Lock Raleigh drug firm BDSI takes aim at $1B opioid drug market

BDSI "We believe we are on course to become one of the first products to compete with Suboxone, a product with sales in excess of a billion dollars annually and currently without competition," CEO Mark Sirgo says.

September 29, 2011

Premium Lock BioDelivery Sciences not phased by drug's trial failure

BDSI The Raleigh-based company also says potential partners are still interested in the pain reliver.

September 29, 2011

Premium Lock BioDelivery Sciences drug candidate fails in trial

BDSI The chronic pain reliver didn't perform better than a placebo in a Phase 3 clinical trial, but the Raleigh company isn'r giving up.

August 24, 2011

Premium Lock BioDelivery Sciences prepares for launch of pain killer in Canada

BDSI The Raleigh-based drug firm gears to sell breakthrough cancer pain reliver after working through production problems.

October 20, 2010

Premium Lock BioDelivery Sciences secures European approval for pain killer

BDSI The decision means $2.5 million in milestone payment for the Raleigh firm.

September 7, 2010

Premium Lock Former exec at Closure Medical joins BioDelivery Sciences

BDSI Benny Ward takes over as business and strategic development director at the drug delivery technology development firm.

May 10, 2010

Premium Lock BioDelivery Sciences wins Canadian approval for painkiller

BDSI The Raleigh-based firm can now sell its “breakthrough” pain killer drug outside of the U.S. It is seeking approval to sell Onsolis in Europe.

Updated April 20, 2010

Premium Lock BioDelivery Sciences stock plunges after $10M deal disclosed

BDSI The announced sale sends BDSI shares down 14 percent from Monday’s closing price of $4.21 per share.

September 2, 2009

Premium Lock BioDelivery Sciences closing lab in New Jersey, cutting five jobs

BDSI Chief science officer is also leaving drug development firm, which recently won FDA approval for its first product.

Techwire Inside Partners
The Skinny: A Blog by Rick Smith

OUR INSIDERS

Vivek Wadhwa
Commentary
Frank Vinluan
Life science
Dr. Mike Walden
Tech economy
Jim Roberts
Entrepreneurship
Scroll

Videos

 
  • Allscripts bringing hundreds of jobs…

  • Nonprofit to handle NC economic…

  • Raleigh goes green, saves green with…

  • Gov. Pat McCrory speaks to NC Chamber

  • NC business leaders unveil job growth…

  • Investment expert: Leading is key in…

  • Retailers tout deals on Twitter

  • Vision for RTP: Social centerpiece